Charcot-Marie-Tooth Disease Therapeutics Market Size (7MM) is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's "Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Charcot-Marie-Tooth Disease Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Charcot-Marie-Tooth Disease Market Report
• In March 2026, NMD Pharma announced a poster presentation and a late-breaking oral presentation highlighting safety and efficacy data from its Phase IIa SYNAPSE-CMT study evaluating ignaseclant (formerly known as NMD670) in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 at a leading Muscular Dystrophy Association Clinical & Scientific Conference.
• In February 2026, Cycle Pharmaceuticals announced that they have completed the acquisition of Applied Therapeutics.
• In February 2026, NMD Pharma announced the topline results from its Phase IIa SYNAPSE-CMT study evaluating ignaseclant in patients living with CMT types 1 or 2. There are currently no FDA-approved therapies for the treatment of CMT disease.
• According to the secondary analysis, the estimated Charcot-Marie-Tooth Disease Prevalence disease ranges from approximately 9-28 per 100,000 population worldwide.
• According to the Charcot Marie Tooth Association, CMT disease affects more than 3 million people globally.
• CMT disease is the most common inherited neuropathy, with an estimated prevalence ranging from 1 in 1,500 to 1 in 10,000 individuals in France.
• As per secondary analysis, CMT1A accounts for approximately 60-70% of all CMT disease cases and is caused by a duplication on chromosome 17p11.2, resulting in overexpression of the Peripheral Myelin Protein 22 (PMP22) gene.
• CMT disease is generally considered a rare disease; however, epidemiological surveys conducted in Europe and the United States have reported a prevalence of approximately 1 per 2,500 people, while in Japan, it is around 1 per 10,000 people.
• CMT disease affects an estimated 1 in 2,500 people in the United States. Although CMT disease is classified as a rare disease (affecting fewer than 200,000 people in the US), experts believe the actual number of affected individuals may be significantly higher. Globally, an estimated 2.6 million people are affected by CMT disease.
• The leading Charcot-Marie-Tooth Disease Companies such as NMD Pharma, Actio Biosciences, Vanda Pharmaceuticals, Augustine Therapeutics and others.
• Promising Charcot-Marie-Tooth Disease Therapies such as Ignaseclant (NMDP-08), ABS-0871, VCA-894A, EN001 and others.

Stay ahead in the Charcot-Marie-Tooth Disease Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Charcot-Marie-Tooth Disease Epidemiology Segmentation in the 7MM
• Total Charcot-Marie-Tooth Disease Prevalent Cases
• Total Charcot-Marie-Tooth Disease Diagnosed Prevalent Cases
• Charcot-Marie-Tooth Disease Gender-specific Diagnosed Prevalent Cases
• Charcot-Marie-Tooth Disease Age-specific Diagnosed Prevalent Cases
• Charcot-Marie-Tooth Disease Type-specific Diagnosed Prevalent Cases
• Total Charcot-Marie-Tooth Disease Treated Cases

Download the report to understand which factors are driving Charcot-Marie-Tooth Disease epidemiology trends @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Charcot-Marie-Tooth Disease Pipeline Analysis
• Govorestat: Applied Therapeutics
Govorestat (AT-007) is a next-generation, potent and selective Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases, including CMT-SORD. Govorestat is a Central Nervous System-penetrant ARI with a highly selective mechanism of action compared to historical ARIs, avoiding off-target effects. Govorestat has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for CMT-SORD. Govorestat has also received ODD from the FDA for the treatment of CMT-SORD.

• Ignaseclant (NMDP-08): NMD Pharma
Ignaseclant (NMDP-08/NMD670), developed by NMD Pharma's, lead development program. It is an investigational first-in-class small molecule inhibitor of the skeletal muscle specific Chloride Ion Channel 1 (CIC-1). NMDP-08 is currently being evaluated in the SYNAPSE-CMT Phase II clinical trial, which began in November 2024.

Charcot-Marie-Tooth Disease Drugs Uptake
The uptake of therapies in CMT disease is expected to remain primarily centered on supportive and rehabilitative management, including physical therapy, orthopedic support, and symptomatic pain treatment, due to the absence of approved disease-modifying therapies. These interventions are anticipated to maintain steady utilization as they remain essential for preserving mobility and functional independence. In contrast, emerging gene-targeted and precision therapies such as siRNA therapies, ASOs, HDAC6 inhibitors, and neuromuscular modulators are expected to witness gradual uptake as clinical evidence and genetic diagnostics continue to advance. Investigational therapies including ignaseclant, VCA-894A, and others are anticipated to drive future innovation, particularly in genetically defined CMT disease subtypes. Future adoption of these therapies will depend on demonstrated efficacy in slowing disease progression, improving motor function, long-term safety, and successful regulatory approvals.

Get In-Depth Knowledge on Charcot-Marie-Tooth Disease Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Charcot-Marie-Tooth Disease Drugs Landscape
With growing understanding of the molecular and genetic basis of CMT disease, the Charcot-Marie-Tooth Disease Therapeutics Market Landscape is increasingly shifting toward precision medicine approaches targeting specific disease-causing mutations such as PMP22 duplication, which accounts for nearly 50-70% of CMT1A cases. Emerging pipeline therapies including ignaseclant (NMDP-08), EDK060 currently being evaluated in an ongoing clinical trial in Canada, VCA-894A, are being developed to improve neuromuscular function, suppress pathogenic gene overexpression, or slow peripheral nerve degeneration. In parallel, increasing adoption of genetic testing and next-generation sequencing is improving subtype identification and supporting patient stratification for targeted clinical development.

Charcot-Marie-Tooth Disease Market Outlook
The Charcot-Marie-Tooth Disease Market Outlook is gradually evolving from a historically supportive care based landscape toward the development of targeted and disease-modifying therapies, although current management continues to rely primarily on physiotherapy, orthopedic support, rehabilitation, and symptomatic pain management. Despite advances in genetic research, there are currently no FDA-approved disease-modifying therapies for CMT disease, highlighting a substantial unmet need and driving increasing investment in gene-targeted approaches, antisense oligonucleotides, RNA-based therapies, and neuromuscular modulators.

Charcot-Marie-Tooth Disease Treatment Landscape
The Charcot-Marie-Tooth Disease Treatment Landscape primarily comprises supportive therapies, symptomatic pharmacological management, and emerging targeted therapies, each aimed at improving mobility, reducing complications, and addressing the underlying genetic mechanisms of disease progression.
• Supportive and rehabilitative therapies: Include physical therapy, occupational therapy, orthopedic support, shoe orthotics, leg braces, and corrective surgery, which currently form the foundation of CMT disease management by helping maintain mobility, muscle strength, and functional independence.
• Symptomatic pharmacological therapies: Mainly include treatments for neuropathic pain and musculoskeletal discomfort, such as pain relievers, TCAs, and anticonvulsants. These therapies help manage symptoms but do not prevent disease progression.
• Targeted and disease-modifying therapies: Emerging pipeline approaches include siRNA therapies, ASOs, HDAC6 inhibitors, and neuromuscular modulators, designed to target underlying genetic abnormalities such as PMP22 overexpression and peripheral nerve dysfunction. Investigational therapies including, ignaseclant, VCA-894A, AGT-100216, and others reflect the growing shift toward precision medicine in CMT disease.

Unlock Strategic Insights with DelveInsight's Comprehensive Charcot-Marie-Tooth Disease Market Report @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Charcot-Marie-Tooth Disease Market Report
• Coverage: 7MM
• Study Period: 2022-2036
• Charcot-Marie-Tooth Disease Companies- NMD Pharma, Actio Biosciences, Vanda Pharmaceuticals, Augustine Therapeutics and others.
• Charcot-Marie-Tooth Disease Therapies- Ignaseclant (NMDP-08), ABS-0871, VCA-894A, EN001 and others.
• Charcot-Marie-Tooth Disease Therapeutic Assessment: Charcot-Marie-Tooth Disease current marketed and Charcot-Marie-Tooth Disease emerging therapies
• Charcot-Marie-Tooth Disease Market Dynamics: Charcot-Marie-Tooth Disease market drivers and Charcot-Marie-Tooth Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Charcot-Marie-Tooth Disease Unmet Needs, KOL's views, Analyst's views, Charcot-Marie-Tooth Disease Market Access and Reimbursement

Table of Contents
1. Charcot-Marie-Tooth Disease Market Report Introduction
2. Executive Summary for Charcot-Marie-Tooth Disease
3. SWOT analysis of Charcot-Marie-Tooth Disease
4. Charcot-Marie-Tooth Disease Patient Share Overview at a Glance
5. Charcot-Marie-Tooth Disease Market Overview at a Glance
6. Charcot-Marie-Tooth Disease Background and Overview
7. Charcot-Marie-Tooth Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Charcot-Marie-Tooth Disease
9. Charcot-Marie-Tooth Disease Current Treatment and Medical Practices
10. Charcot-Marie-Tooth Disease Unmet Needs
11. Charcot-Marie-Tooth Disease Emerging Therapies
12. Charcot-Marie-Tooth Disease Market Outlook
13. Country-Wise Charcot-Marie-Tooth Disease Market Analysis
14. Charcot-Marie-Tooth Disease Market Access and Reimbursement of Therapies
15. Charcot-Marie-Tooth Disease Market Drivers
16. Charcot-Marie-Tooth Disease Market Barriers
17. Charcot-Marie-Tooth Disease Appendix
18. Charcot-Marie-Tooth Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.